Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of FK463 for the Treatment of Invasive Aspergillosis

This study has been completed.
Sponsor:
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00036166
First received: May 8, 2002
Last updated: April 4, 2011
Last verified: April 2011
  Purpose

The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.


Condition Intervention Phase
Aspergillosis
Drug: FK463
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Enrollment: 326
Study Start Date: January 1999
Study Completion Date: December 2002
Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Detailed Description:

This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Has proven or probable systemic infection with Aspergillus species

Exclusion Criteria

  • Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal
  • Has bronchopulmonary aspergillosis, aspergillomas, sinus aspergillosis or external otitis but does not have histologic evidence of tissue invasion
  • Has life-expectancy judged to be less than 5 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036166

Locations
Austria
Medizinische Univ.-Klinik
Graz, Austria, 8036
Krankenhaus Elisabethinen Linz
Linz, Austria, A-4010
France
Hopital Henri Mondor, Service d'Hematologie Clinique
Creteil, France, 94010
Hotel Dieu, Service d'Hematologie
Nantes, France, 44093
Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle
Paris, France, 10
Hopital Necker Enfants Malades, Service d'Hematologie
Paris, France, 75015
Germany
Johann Wolfgang Goethe Universitat, Medizinische Klinik III
Frankfurt, Germany, D-60590
Westpfalz Krankehaus
Kaiserslautern, Germany, D-67655
Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie
Leipzig, Germany, D-04103
Klinikum der Stadt, Medizinische Klinik A
Ludwigshafen, Germany, D-67063
Uniklinik Mainz
Mainz, Germany, 55101
LMU Munchen, Hamatopoetische Zell - Transplantation
Munchen, Germany, D-81366
Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie
Wurzburg, Germany, E-97070
Italy
Nationale Institute for Cancer Research
Genova, Italy, I 16132
Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera
Milano, Italy, 20162
Poland
Institute of Haematology and Blood Transfusion
Warsaw, Poland, 00-957
Spain
Hospital Clinic I provencial, Servicio Enfermadades Infecciosas
Barcelona, Spain, ES 28041
Hospital Doce de Octubre, Servicio de Microbiologia y Enfermadades Infecciosas
Madrid, Spain, ES 28041
Hospital Gregorio Maranon, Servicio de Enfermadades Infecciosas
Madrid, Spain, ES 28007
Sweden
Huddinge University Hospital, Dept. of Transplantation Surgery/Immunology
Huddinge, Sweden, SE141 86
United Kingdom
Royal Free Hospital, Dept. of Haematological Oncology
London, United Kingdom, NW3 2QG
Christie Hospital NHS Trust
Manchester, United Kingdom, M20 4BX
Royal Marsden Hospital
Sutton Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Astellas Pharma Inc
  More Information

Publications:
Responsible Party: Disclosure Office Europe, Astellas Pharma Europe BV
ClinicalTrials.gov Identifier: NCT00036166     History of Changes
Other Study ID Numbers: FG463-21-01, 98-0-046
Study First Received: May 8, 2002
Last Updated: April 4, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:
Aspergillus
Anti-Fungal

Additional relevant MeSH terms:
Aspergillosis
Dermatomycoses
Hyalohyphomycosis
Infection
Mycoses
Skin Diseases
Skin Diseases, Infectious

ClinicalTrials.gov processed this record on November 23, 2014